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1.  Introduction  
Diabetes  mellitus  is  an  incurable  disease  [1]  resulting  from  an  insufficiency  of  insulin  in  the  body  
[2],   causing   elevated   blood-­‐‑glucose   levels,   known   as   hyperglycaemia,   or   reduced   glucose  
concentrations,   known   as   hypoglycaemia   [3,4].   Insulin   is   a   hormone   which   is   synthesised   and  
secreted   from   the  pancreas   to  mediate  metabolic   reactions   involving  glucose   [5,6].   In  doing   so,   it  
initiates  glucose  uptake  by  cell   types  in  the  body,  hence  reducing  glucose  concentrations  in  blood  
[2,7].  Diabetes  has  been  associated  with  many  medical  conditions,  including  coeliac  disease,  cystic  
fibrosis,   tuberculosis   and   heart   disease.   Such   complications   can   result   in   retinopathy   leading   to  
blindness,  nephropathy  giving  rise  to  renal  failure,  peripheral  nerve  damage  with  increasing  risks  of  
extremity  (foot)  ulcers,  amputation,  cardiovascular  diseases  or  even  cancer  [2,4,6].  Diabetes  has  been  
described  as  a  “silent  epidemic”  in  a  review  by  Nwaneri  detailing  the  origin  of  the  disease  [8]  and  
since   its   discovery,   great   efforts   have   been   made   to   achieve   efficient   diagnosis,   monitoring   and  
treatment.  
A  plethora  of  biosensors  have  been  developed  to  provide  diagnostic   information  regarding  a  
patient’s  health  status.  Many  different  types  of  sensors  have  been  investigated,  and  a  2010  review  by  
Toghill  and  Compton  provides  a  great   insight   into  enzymatic  and  non-­‐‑enzymatic  electrochemical  
glucose  sensing  approaches  studied  over  the  past  decade  [9].  Spectroscopic  methods  for  non-­‐‑invasive  
glucose  detection  have  also  been  growing  in  popularity,  with  Raman  and  infrared  spectroscopy  being  
the  focus  of  particular  attention  [10–12].  For  applications  of  clinically  relevant  biosensors  the  reader  
is  directed  to  excellent  reviews  by  Corrie  et  al.  [13]  and  Yoo  et  al.  [14].  However,  the  real  challenge  
that  remains  is  the  creation  of  biosensors  for  daily  use  by  patients  in  personalised  monitoring  [14].  
Several  reviews  focusing  on  sensor  integration  into  wearable  platforms  have  been  published  recently  
[15–17],  therefore,  this  review  focuses  solely  on  recent  advances  pertaining  to  biological  fluids  other  
than  blood,  such  as  interstitial  fluid,  sweat,  breath,  saliva  and  ocular  fluid,  and  focusing  particularly  
on  non-­‐‑invasive  approaches  which  may  enable  continuous  glucose  monitoring  for  diabetics.  
2.  Glucose  Monitoring  
2.1.  Glucose  Monitoring  Methods  in  Blood  
As   a   preventative   treatment   or   cure   for   diabetes   is   yet   to   be   developed,  managing   the   life-­‐‑
impeding  conditions  of  this  disease  is  currently  the  most  successful  means  for  its  control.  Monitoring  
   
glucose   levels   in   blood,   as   a   disease  marker,   has   proven   to   prolong   life   expectancy   by   enabling  
diabetics  to  manage  episodes  of  hypo-­‐‑  or  hyperglycaemia,  hence  providing  better  control  over  their  
condition  and  preventing  some  of  the  debilitating  side  effects  [18,19].  In  addition,  glucose  monitoring  
can   be   used   to   optimise   patient   treatment   strategies,   and   provide   an   insight   into   the   effect   of  
medications,  exercise  and  diet  on  the  patient  [13].  Although  blood-­‐‑glucose  monitoring  is  the  gold-­‐‑
standard  medium  for  glucose  sampling,  measurements  carried  out  in  this  fluid  are  invasive  [16,18].  
Blood-­‐‑glucose  concentrations  are  typically  in  the  range  of  4.9–6.9  mM  for  healthy  patients,  increasing  
to  up  to  40  mM  in  diabetics  after  glucose  intake  [2,18–21].  
Clark  and  Lyons  at  the  Children’s  Hospital  in  Cincinnati  proposed  in  1962  the  first-­‐‑generation  
of  glucose  biosensors  [22].  These  sensors  were  initially  based  on  an  electrochemical  approach,  which  
used  the  enzyme  glucose  oxidase  (GOx)  [13].  Electrochemical  sensors  were  chosen  for  blood-­‐‑glucose  
measurements  due  to  their  high  sensitivity,  on  the  order  of  µμM  to  mM,  good  reproducibility  and  ease  
of  fabrication  at  relatively  low  cost  [18].  GOx  was  employed  as  the  enzymatic  basis  for  the  sensor,  
owed  to  its  high  selectivity  for  glucose.  Less  common  enzymes,  such  as  hexokinase  and  glucose-­‐‑1-­‐‑
dehydrogenase   were   also   used   for   glucose  measurements   [23,24],   but   GOx   can   tolerate   extreme  
changes   in  pH,   temperature  and   ionic   strength   in   comparison  with  other   enzymes.  Withstanding  
these  conditions  can  be  important  during  any  manufacturing  processes,  making  it  a  prime  candidate  
for  glucose  monitoring  devices  [25,26].     
GOx   catalyses   the   oxidation   of   glucose   to   gluconolactone   in   the   presence   of   oxygen,   while  
producing   hydrogen   peroxide   (H2O2)   and  water   as   by-­‐‑products   (Scheme   1)   [13].   Gluconolactone  
further  undergoes  a  reaction  with  water  to  produce  the  carboxylic  acid  product,  gluconic  acid.  GOx  
requires   a   redox   cofactor   to   carry   out   this   oxidation   process,   where   flavin   adenine   dinucleotide  
(FAD+)  is  employed.  FAD+  is  an  electron  acceptor  which  becomes  reduced  to  FADH2  during  the  redox  
reaction  [27].  Subsequent  reaction  with  oxygen  to  produce  H2O2  regenerates  the  FAD+  cofactor.  This  
reaction   occurs   at   the   anode,  where   the   number   of   transferred   electrons   can   be   correlated   to   the  
amount  of  H2O2  produced  and  hence  the  concentration  of  glucose  [27].  
  
Scheme  1.  Conversion  of  glucose  to  gluconic  acid  using  glucose  oxidase.  Adapted  from  [28].  
In   the   sensor   design   presented   by   Clark   and   Lyons,   indirect   quantification   of   glucose  
concentrations  was  achieved  by  placing  a  thin  layer  of  the  GOx  enzyme  on  a  platinum  electrode  via  
a  semipermeable  dialysis  membrane.  This  sensor  measured  the  decrease  in  oxygen  concentration  and  
the  liberation  of  hydrogen  peroxide,  which  was  proportional  to  the  glucose  concentration  [22].  The  
main   obstacle   to   overcome  with   this   approach  was   the   interference   of   other   electroactive   species  
present  in  blood,  such  as  ascorbic  acid  and  urea  [13,29].  This  approach  was  further  developed  in  1975,  
when   the   first   successful   commercial   sensor   based   on  GOx  was  made   available   [13].   This   sensor  
directly  measured   glucose   concentrations   by   amperometric   detection   of   hydrogen   peroxide.   The  
electrochemical  signal   required  a  high  operating  potential  and  due   to   the  expensive  nature  of   the  
platinum  electrode  used,  the  use  of  this  device  was  strictly  confined  to  clinical  settings  [13].  This  led  
to  the  second  generation  of  glucose-­‐‑biosensors  in  the  1980s  [29].  
In  the  design  of  first  generation  sensors,  oxygen  was  employed  as  the  electron-­‐‑acceptor,  which  
can  result  in  errors  from  variations  in  oxygen  tension  and  limitations,  known  as  the  oxygen  deficit  
[30].   This   deficit   is   caused   by   oxygen   concentrations   being   one   order   of   magnitude   lower   than  


























a  synthetic  electron  redox  mediator  in  second  generation  sensors  [30].  The  evolution  of  this  sensing  
approach   also   led   to   the   development   of   disposable   enzyme   electrode   strips,   which   were  
accompanied  by  a  pocket-­‐‑size  blood-­‐‑glucose  meter  [31,32].  Each  strip  housed  miniaturised  screen-­‐‑
printed  working  and  reference  electrodes,  where  the  working  electrode  was  coated  with  the  required  
sensing   components;   glucose   oxidase,   an   electron-­‐‑shuttle   redox   mediator,   stabilizer   and   linking  
agent.  These  revolutionary  second-­‐‑generation  glucose  sensors  directly  resulted  in  the  advent  of  self-­‐‑
monitored  glucose  management,  known  as  the  “finger-­‐‑pricking”  approach.  
Currently,   the   most   widely   used   self-­‐‑monitoring   method   involves   this   ‘finger-­‐‑pricking’  
approach,  is  enzymatic-­‐‑based,  and  involves  sampling  blood  from  a  finger  via  pricking,  to  be  analysed  
by  in  vitro  methods  using  test  strips  and  a  glucometer  (Figure  1)  [7,21,33–42].  The  effectiveness  of  
this  method  relies  on  strict  compliance,  which  can  be  negatively  influenced  by  time  constraints,  pain,  
and  inconvenience  [43].  It  is  also  not  a  continuous  monitoring  approach  [21,36,37,39,44]  and  needs  to  
be   carried   out   at   multiple   intervals   throughout   the   day   to   help   manage   elevated   glucose   levels  
[18,20,21,37],   especially   after   meals   [41],   exercise   [20,41]   and   dosing   of   insulin   medication  
[20,41,43,45].  Moreover,   a  non-­‐‑continuous  method   such  as   this   can  overlook  periods  of  hyper-­‐‑   or  
hypoglycaemia   which   occur   outside   of   the   sampling   window   [43].   Recent   developments   in  
implantable  sensors,  on  the  other  hand,  can  be  used  to  incorporate  insulin  pumps,  which  allow  for  
instant  insulin  administration  [20,35,42,43,45].  
  
Figure  1.  Finger  pricking  device  (left).  A.  Lancet  needle;  B.  Blood  sample  on  test-­‐‑strip;  C.  Glucose  
meter   displaying   glucose   concentration   in  mmol/L.  Continuous   glucose  monitor   (right).  Adapted  
from  [46,47].     
In  the  early  1970s,  Albisser  et  al.  and  Shichiri  et  al.  first  introduced  in  vivo  continuous  glucose  
monitoring   using   an   artificial   pancreas   [48,49].   The   artificial   pancreas   design   was   based   on  
continuous  glucose  monitoring,  where  the  device  would  remove  blood  from  the  body  to  an  external  
benchtop   analyser   that  was   connected   to   an   insulin   pump.  As   this   suggests,   the   device  was   not  
implanted  and  therefore  not  portable,  although  it  was  named  the  ‘artificial  pancreas’.  This  led  to  the  
development   of   a   third   generation   of   glucose   biosensor,   which   was   subcutaneously   implanted  
(Figure  1).  Although  the  device  could  analyse  glucose  concentrations  in  blood  using  GOx,  this  was  
considered  an  invasive  method  [50].  It  wasn’t  until  the  late  1990s  that  the  first  commercially  available  
personalised  in  vivo  glucose  monitor  was  launched  by  Medtronic  Minimed  Inc.  (Sylmar,  CA,  USA)  
[29].  Unfortunately,  the  device  could  not  provide  real-­‐‑time  information,  with  data  being  accessed  by  
a   physician   every   3   days   [13].   Although   implantable   glucose   monitoring   systems   offer   regular  
glucose  level  readings,  this  approach  isn’t  recommended  for  all  diabetics,  due  to  its  invasive  nature  
[18]  and  some  continuous  glucose  monitoring  methods  have  been  reported  to  show  inaccuracies  of  
up   to   21%   [51].   These   inaccuracies   are   often   attributed   to   sensor   drift,   caused   by   changes   in   the  
catalytic  performance  of  the  enzyme.  This  requires  the  device  to  be  periodically  recalibrated  via  the  
finger-­‐‑pricking   method   [52].   Despite   current   commercially   available   glucometers,   such   as   the  
Freestyle-­‐‑Navigator  by  Abbott  (Abbott  Park,  IL,  USA),  providing  real-­‐‑time  measurements  every  1–5  
min,   the   longest  working  model  without   calibration   is   approximately   two  weeks.   Consequently,  
there   is   high   consumer  demand   for   a   continuous   glucose  monitoring   system  which   can   quantify  
   
glucose  concentrations  without  frequent  calibration.  Although  blood  remains  the  most  studied  body  
fluid  for  such  measurements,  other  more  accessible  biological  fluids  such  as  interstitial  fluid,  ocular  
fluid,   sweat,   breath,   saliva   or   urine   have   been   investigated   as   alternative   sample  media   for   non-­‐‑
invasive  continuous  monitoring  (Table  1)   [16–19].   It   is   likely   that   the  development  of  a  device   for  
glucose   sensing   with   a   working   model   of   more   than   two   weeks   may   target   one   of   these   more  
accessible  fluids.  
Table  1.  Summary  of  glucose  concentrations  postprandial  and  pH  values  measured  in  physiological  
fluids  of  healthy  and  diabetic  patients.  
Physiological  Fluid   Biomarker   Concentration  for  Healthy  Patients’   Concentration  for  Diabetic  Patients’   pH  
Blood   Glucose   4.9–6.9  mM  [19]   2–40  mM  [20,40]   7.35–7.45  [14]  
Interstitial  Fluid   Glucose   3.9–6.6  [53]   1.99–22.2  [54]   7.2–7.4  [14]  
Urine   Glucose   2.78–5.55  mM  [18]   >5.55  mM  [18]   4.5–8  [14]  
Sweat   Glucose   0.06–0.11  mM  [55]   0.01–1  mM  [55]   4.5–7  [56]  
Saliva   Glucose   0.23–0.38  mM  [57]   0.55–1.77  mM  [57]   6.2–7.6  [58]  
Ocular  Fluid   Glucose   0.05–0.5  mM  [21]   0.5–5  mM  [20,21]   6.5–7.6  [18]  
Breath   Acetone   0.1–2  ppm  [59]   0.1–103.7  ppm  [59]   7.4–8.1  [60]  
2.2.  Monitoring  Glucose  in  Alternative  Physiological  Fluids  
2.2.1.  Interstitial  Fluid  
Interstitial  fluid  is  the  extracellular  fluid  which  surrounds  tissue  cells.  It  has  significant  potential  
for  medical   diagnostics   as   it   possesses   a   similar   composition   of   a   number   of   clinically   important  
biomarkers   to   blood   [14,15].   Blood   and   the   surrounding   vascularised   tissue   readily   exchange  
biological  analytes  and  small  molecules  by  diffusion  with  the  interstitial  fluid  [14].  As  a  result,  the  
interstitial   fluid   can   offer   valuable   information   about   a   patient’s   health   and   has   been   used   for  
minimally   invasive   determination   of   inherited  metabolic   diseases,   organ   failure   or   drug   efficacy.  
Consequently,  substantial  efforts  have  focused  on  non-­‐‑invasive  glucose  sensing  in  this  physiological  
fluid  to  provide  information  regarding  a  patient’s  glycaemic  state.     
Methods  for  monitoring  glucose  via  the  skin  have  become  very  popular  in  recent  years,  where  
these   approaches   have   been   developed   to   counteract   the   challenges   associated   with   patient  
compliance   and   invasive   monitoring   [15].   Some   of   these   approaches   include   sensing   by   optical  
detection  such  as  light  absorption  or  fluorescence  detection,  ultrasound  or  sonophoresis,  polarimetry,  
heat   or   thermal   emission,   electromagnetic   techniques,   photoacoustic   detection,   Raman   or  
bioimpedance   spectroscopy,   electrochemical   methods   and   reverse   iontophoresis-­‐‑based  
electrochemical  sensing,  among  others  (Table  2)  [15,19,61–63].  A  limitation  of  reverse  iontophoresis  
is   that   typically   stable   measurements   can   only   be   reliably   recorded   for   a   period   of   24   h   before  
calibration  of  the  device  is  required.  This  is  thought  to  result  from  the  initiation  of  the  skin  healing  
process  as  interstitial  fluid  sampling  is  achieved  by  breaching  the  skin  barrier  [62].  The  GlucoWatch  
was   developed   as   a   wearable   device   which   was   initially   brought   to   market   for   non-­‐‑invasive  
continuous  monitoring  of  glucose  [1,20,33,35,45].  This  technique  used  reverse  iontophoresis  to  extract  
interstitial  fluid  through  the  skin,  and  measure  glucose  levels  [1,33]  in  a  pH  range  of  pH  7.2–7.4  [14].  
Although  the  GlucoWatch  was  a  considerable  advancement  towards  non-­‐‑invasive  and  continuous  
glucose   monitoring,   the   approach   was   hampered   by   the   need   for   periodic   recalibration   by   the  
pricking  method  [13,35,64],  thereby  resulting  in  an  increase  in  costs  for  testing  equipment  and  patient  
care  [45].  Other  drawbacks  included  long  warm  up  times,  sweating  and  skin  rash  with  irritation  [35],  




Table  2.  Summary  definitions  of  specialised  approaches  for  glucose  sensing  in  interstitial  fluid.  
Sensing  Technique   Explanation   Reference  
Reverse  Iontophoresis  
Reverse  iontophoresis  is  the  passing  of  a  current  over  the  skin  to  drive  ions  
from  the  interstitial  fluid  and  onto  the  surface  of  the  skin,  where  they  can  
be  analysed.  This  results  due  to  the  increased  negative  charge  across  the  
skin  which  drives  cations  from  the  body  on  to  the  skin  surface.  
[65]  
Thermal  Emission  
Thermal  emission,  infrared  thermography,  infrared  imaging  or  thermal  
imaging  is  a  non-­‐‑contact  tool  that  uses  the  surface  body  temperature  to  
gain  insight  in  to  the  detection  of  diseases,  flow  of  blood  or  muscular  
performance  of  an  individual.  
[66]  
Photoacoustic  Detection  
Photoacoustic  spectroscopy  uses  a  form  of  light  absorption  to  detect  an  
analyte  concentration  in  a  biofluid,  such  as  blood.  Light  from  a  laser  source  
is  absorbed  by  blood  which  generates  heat  in  a  localised  region.  The  heat  
induces  ultrasonic  pressure  waves  in  blood,  which  can  be  detected  by  an  
ultrasonic  transducer  and  directly  related  to  an  analyte  concentration  that  
absorbs  at  the  laser  wavelength.     
[10]  
Sonophoresis   Transdermal  delivery  of  drugs  by  ultrasound.   [67]  
Sode  et  al.  have  also  developed  a  self-­‐‑powered  implantable  continuous  monitoring  device  called  
the  BioRadioTransmitter  for  use  in  an  artificial  pancreas  [68].  In  this  instance,  the  device  is  composed  
of   a   capacitor,   radio   transmitter   and   receiver.   In   the   presence   of   glucose,   the   capacitor   of   the  
BioRadioTransmitter  device  discharges  a  radio  signal,  which  is  received  and  amplified  by  the  radio  
receiver.  The  change  in  transmission  frequency  is  then  related  to  the  glucose  concentration  [68].     
Microneedles  and  microneedle  arrays  have  also  garnered  a  lot  of  interest  over  recent  years  for  
interstitial  fluid  sensing,  since  this  approach  can  offer  minimally  invasive  methods  for  bio-­‐‑sensing.  
This  concept  was  used  in  the  development  of  a  glucose-­‐‑sensing  patch  by  Jina  et  al.  [62].  The  device  
was  designed  in  two  compartments;  the  first  containing  the  microneedle  array  and  glucose  biosensor  
with  the  second  containing  the  electronics  (Figure  2).  This  miniaturised  device  spans  a  total  area  of  6  
×  6  mm  in  which  it  contains  200  hollow  microneedles  (300  µμm  in  length  with  a  50  ×  50  µμm  lumen)  
[62].   Three   screen-­‐‑printed   electrodes   were   used   for   quantifying   glucose   concentrations   in   the  
interstitial   fluid,   including   a   Pt-­‐‑C  working   electrode   covered  with   a   layer   of   cross-­‐‑linked   bovine  
albumin  serum  and  glucose  oxidase.  The  sensing  device  was  attached  to  the  skin  by  an  adhesive  layer  
contouring  the  perimeter  of  the  sensing  pod.  Detection  was  performed  upon  glucose  diffusion  into  
the  microneedle  array,  wherein  GOx  could  react  to  produce  hydrogen  peroxide.  The  production  of  
hydrogen  peroxide  detected  by  the  working  electrode  was  proportional  to  the  glucose  concentration  
[62].   The   electronics   module   of   this   device   required   the   use   of   an   external   potentiostat,   a  
microprocessor  and  a  battery  to  power  the  device  [62].  
  
Figure  2.  Schematic  of  the  microneedle  glucose-­‐‑sensing  patch  on  the  forearm.  Adapted  from  [62].  
A   microneedle   patch   platform   allows   the   device   to   be   in   constant   contact   with   the   skin,  
providing  permanent  access  to  the  interstitial  fluid,  and  enabling  this  device  to  operate  continuously  






interstitial   fluid  sampling,  as   the  microneedles  do  not  reach   the  dermis   layer.  This  minimises  any  
damage   to   blood-­‐‑capillaries   and   nerve   endings   found   in   the   dermis   layer.   Moreover,   as   the  
microneedles  penetrate  the  skin,  contamination  by  sweat  is  avoided  [16].  Tests  have  shown  that  this  
device  can  operate  successfully  for  up  to  72  h  with  only  a  17  minute  lag  time  caused  by  the  passive  
diffusion  of  analytes  from  blood  into  the  interstitial  fluid  matrix  [62].  To  increase  the  lifetime  of  the  
device,  the  skin  healing  process  must  be  inhibited.  This  could  potentially  be  achieved  by  designing  a  
sensing   patch   with   microneedles   of   optimal   length,   width,   tip   and   pitch   characteristics,   and   by  
coating  the  microneedles  with  a  biocompatible  material  exhibiting  similar  mechanical  properties  to  
that  of  biological  tissue.  Currently,  the  device  must  be  recalibrated  daily  by  the  finger-­‐‑prick  approach  
[62].  Potential  clogging  of  the  microneedles  and  the  distortion  of  their  shape  upon  penetration  of  the  
skin  can  also  affect  the  dynamics  of  sampling.  Despite  these  shortcomings,  this  novel  device  holds  
great  potential  for  non-­‐‑invasive  continuous  glucose  monitor.  
Russell  et  al.  [69],  were  the  first  to  introduce  a  tattoo  sensing  technology  using  hydrogel  glucose-­‐‑
sensing  microspheres.  Zhi  et  al.  further  developed  this  technology  by  encapsulating  the  sensors  in  a  
thin   film,  which   offered   the   advantage   of   fast   analyte   transport   through   the   device   [63].   This  was  
achieved   by   fabricating   microvesicles   through   a   layer-­‐‑by-­‐‑layer   approach,   which   encapsulated   a  
fluorescent   labelled   protein   as   the   glucose   receptor.   When   glucose   bound   to   the   protein,   a  
conformational   change   was   induced   in   the   protein,   which   increased   the   polarity   of   the   sensing  
environment.   As   a   result,   the   fluorescence   became   increasingly   quenched   as   the   concentration   of  
glucose  increased  [63].  These  microvesicles  were  then  implanted  in  to  the  dermis  layer  of  the  skin  in  a  
mouse  ear,  and  the  fluorescence  lifetime  was  measured  for  glucose  concentrations  in  a  range  of  1–100  
mM.   An   advantage   of  measuring   fluorescence   lifetime  meant   that   important   issues   such   as   light  
scattering  and  photobleaching  could  be  avoided.  This  approach  could  also  be  designed  for  pancreatic  
islet  transplants,  which  are  a  known  treatment  procedure  for  Type  1  diabetes  patients.  It  is  commonly  
seen  that  these  cells  are  subject  to  early  destruction  or  rejection  from  the  innate  host  immune  systems  
upon   transplantation.   To   overcome   this   challenge,   a   biocompatible   encapsulation   method   using  
fluorophores  with  excitation  wavelengths  in  the  NIR  region  holds  the  potential   for   improving  the  
efficacy   of   this   transplantation   approach.   As   cellular   tissues   are   transparent   to   NIR   light,  
measurements   taken   via   the   surface   of   the   skin   could   facilitate   continuous   non-­‐‑invasive   sensing  
[63,70].  Other  methods  for  interstitial  fluid  sensing  which  are  currently  under  development  include  
sensors  based  on  impedance  spectroscopy  (Pendra,  by  Pendragon  Medical  Ltd.,  Zurich,  Switzerland)  
and  optical   transducers   (C8  MediSensors  Optical  Glucose  Monitor™  System,  by  C8  MediSensors,  
Inc.,  San  Jose,  CA,  USA).  
2.2.2.  Urine  
Since  1841,  urine  has  been  used  as  a  diagnostic  fluid  for  diabetes  [71].  It  has  been  extensively  
studied,  as  it  can  be  easily  and  non-­‐‑invasively  collected  [14,18].  Urine  is  composed  of  metabolites,  
such  as  glucose,  proteins  and  nitrates,  as  well  as  other  dissolved  salts,  such  as  sodium  and  potassium.  
As  a  result,  the  pH  of  urine  fluctuates  between  acidic  pH  4.5  to  basic  pH  8  [14].  Due  to  the  intermittent  
nature   of   this   fluid,   where   collection   is   required   for   sampling,   it   cannot   be   incorporated   into   a  
continuous  glucose-­‐‑monitoring  device  [72].  Glucose  can  be  found  in  urine  when  it  is  excreted  from  
blood  in  elevated  levels  and  as  a  result,  this  fluid  has  been  investigated  for  the  diagnosis  of  diabetes.  
A  positive  result  occurs  when  the  glucose  levels  in  urine  are  in  the  2.78–5.55  mM  range  [18].  
2.2.3.  Sweat  
Sweat   is   one   of   the   most   accessible   body   fluids,   where   its   primary   biological   role   is   for  
thermoregulation  [73].  Conveniently,  for  sampling  purposes,  eccrine  glands  that  excrete  sweat  can  
be   found   all   over   the   body,   where   they   are   particularly   concentrated   in   multiple   locations,   for  
example  in  the  hands,  feet,  lower  back  and  underarm  [56].  Sweat  has  been  exploited  for  diagnostic  
purposes,   in   particular   for   the   detection   of   disease  markers   such   as   sodium,   potassium,   calcium,  
phosphate  and  glucose   [16].   It   is  also  known   that   small-­‐‑molecule  drugs  and   their  metabolites  are  
present  in  sweat,  thereby  allowing  the  evaluation  of  drug  efficacy  [74].  Sweat  can  be  continuously  
   
accessed   and   its   production   can   be   stimulated   on-­‐‑demand   at   certain   locations,   for   example   by  
iontophoresis  [56].  By  placing  sensors  in  close  contact  with  the  skin,  sweat  samples  can  be  processed  
rapidly  without  contamination  [56].  For  many  years,  sweat  has  been  used  as  a  sampling  medium  of  
interest   in   sensing   devices   for   confirming   diseases,   such   as   cystic   fibrosis   and   for   gaining   other  
valuable  information,  relating  to  electrolyte  balance,  diet,  injury,  stress,  medications  and  hydration.  
The   hydration   status   of   individuals   has   become   a   relatively   new   area   of   interest   for  monitoring  
human  performance,  resulting  in  an  increase  in  wearable  smart  devices  on  the  global  market  [16,75].  
Most  analytes  contained  in  sweat  tend  to  vary  significantly  between  basal  and  exercising  states,  as  
well  as  between  individuals.  The  reported  glucose  level  in  sweat  for  healthy  patients  is  between  0.06  
and  0.11  mM  and  between  0.01  and  1  mM  for  diabetics  [55].  The  fluctuations  in  analyte  concentrations  
result  in  a  broad  pH  range  of  sweat,  typically  between  pH  4.0–6.8  during  exercise  [76,77],  which  can  
impact  on  the  effectiveness  of  chemical-­‐‑sensing  or  biosensing  techniques  chosen  for  disease  diagnosis  
or  monitoring  [14].  
An  example  of  a  device  developed  for  sweat  sensing  is  SwEatch  by  Diamond  and  co-­‐‑workers  
[73].  This  device  was  designed  for  sodium  analysis  in  sweat  and  was  fabricated  using  3D-­‐‑printing  
methods   for   the   sensor   casing   and   sensor   connections   (Figure   3).   The   device  was   powered   by   a  
lithium  battery  that  allowed  the  device  to  function  continuously  for  up  to  3  h  [73].  This  approach  
could   be   easily   adapted   for   glucose   sensing   in   sweat   by   introducing   a   glucose   sensor   into   the  
platform.  
In  2010,  Heikenfeld  et  al.  began  fabricating  sweat-­‐‑sensing  patches   that  could  stimulate  sweat  
production,  measure  analyte  concentrations  in  sweat  wirelessly,  and  transmit  that  information  to  a  
smartphone  [75].  This  research  aimed  to  determine  physical  fatigue  in  athletes  by  measuring  their  
dehydration   status   using   their   sweat.   Dehydration   is   known   to   be   a   reoccurring   problem   for  
professional  athletes  and  by  alerting  an  athlete  of   their  oncoming  over-­‐‑exertion,   instances  such  as  
cramping  and  electrolyte  imbalance  could  be  avoided,  while  simultaneously  prompting  the  uptake  
of   fluids   [75].   Heikenfeld   has   written  many   reviews   in   this   area,   and   his   outlook   for   the   future  
suggests  that  technology  is  advancing  towards  glucose  sensing  in  sweat  [56,74,75].  
Wang  et  al.  [78–80]  have  also  recently  been  working  towards  the  development  of  a  continuous  
and   non-­‐‑invasive   sensing   device   for   detecting   specific   analytes   in   sweat   using   electrochemical  
sensing.  In  their  approach,  they  have  investigated  a  range  of  innovative  sensing  platforms,  including  
wristbands  [78],  stick-­‐‑on  flexible  sensors  [79]  and  traditional  eyeglasses  (Figure  4)  [80].  By  adapting  
spectacles,  Wang  et  al.  have  created  a  device  that  can  be  easily  integrated  into  an  individual’s  lifestyle.  
This  device  contains  an  amperometric  lactate  biosensor  connected  on  to  one  of  the  nose-­‐‑bridge  pads  
and  a  potentiometric  potassium  ion-­‐‑selective  electrode  on  to  the  other  (Figure  4)  [80].  Both  sensors  were  
interfaced  with   an   electronic   backbone   on   the   glasses’   arms.   The  device   could   successfully   sense  
lactate  and  potassium  ions  in  sweat  for  a  few  hours  continuously.  The  positioning  of  the  sensors  on  
separate  nose  pads  also  minimised  cross-­‐‑talk  and  facilitated  separate  fabrication  and  replacement.  
These   instrumented   eyeglasses  were   coupled  by  Bluetooth  wireless  data   to   a   remote  mobile  host  
device  for  data  analysis  and  visualisation.  In  this  approach,  the  nose-­‐‑bridge  pads  were  designed  so  
that  the  pads  could  be  interchanged  with  others  for  multifunctional  sensing  applications  [80].  Wang  
and   co-­‐‑workers   also   demonstrated   that   by   interchanging   the   lactate   sensing   pad   for   a   glucose  
sensitive  one,  the  spectacles  could  be  used  to  monitor  glucose  concentrations  in  human  sweat.  The  
results  showed  good  blood-­‐‑sweat  glucose  correlations  in  healthy  individuals  when  the  blood  levels  
were  compared  with  a  commercially  available  blood-­‐‑glucose  meter  [80].  
   
  
Figure  3.  SwEatch:  watch-­‐‑sensing  platform  for  sodium  analysis  in  sweat.  1.  Electronics.  2.  3D  printed  
casing  3.  Microfluidic  chip  and  ion-­‐‑selective/ion-­‐‑specific  electrode  4.  3D  printed  sweat  harvester  and  
sensor  connections.  Reproduced  from  [73],  Copyright  (2016),  with  permission  from  John  Wiley  and  
Sons.  
  
Figure  4.  Schematic  representation  of   the  eyeglasses  biosensor  system,  which   integrates  a  wireless  
circuit   board   along   the   arms   of   the   spectacles   and   two   electrochemical   sensors   for   lactate   and  
potassium  on  to  the  nose-­‐‑bridge  pads.  A  schematic  of  the  lactate  sensor  (left)  and  potassium  sensor  
(right),  along  with  the  corresponding  recognition  and  transduction  events   is  also  shown.  Adapted  
from  [80].  
Gao  et  al.  [81]  recently  reported  a  non-­‐‑invasive  and  continuous  wearable  glucose-­‐‑sweat  sensing  
device  (Figure  5).  Sensors  integrated  in  to  this  Bluetooth-­‐‑enabled  wristband  detect  skin  temperature,  
sodium,  potassium,  lactate  and  glucose  concentrations  in  sweat  [81].  An  advantage  of  this  approach  
is  the  use  of  multiple  sensors  which  overcomes  limitations  of  single,  stand-­‐‑alone  sensors  [74,81].  Due  
to   the   complex   nature   of   sweat,  multiple   sensors   are   required   to   provide   a  more   comprehensive  
profile  of  sweat  composition  and  enable  data  cross-­‐‑comparisons.  For  example,  it  is  known  that  the  
potassium   concentration   in   sweat   is   quite   stable   during   basal   and   exercising   states.   As   a   result,  
potassium  levels  can  be  used  as  a  reference   for  comparing   the   fluctuating  concentrations  of  other  
analytes,  such  as  glucose  and  enable  real   fluctuations  to  be  distinguished  from  artefacts  [81].  This  
device  was  designed  to  exhibit  similar  form  factors  of  existing  devices,  such  as  the  fitness  wristbands  
by  Fitbit   Inc.   (San  Francisco,  CA,  USA),   thereby   encouraging  user  uptake   to   create   a  pathway   to  
commercialisation.  The  sensors  were  tested  individually  in  situ  and  collectively  in  the  device.  The  
device   analyte   readings   showed   good   correlations   to   the   normal   concentration   ranges   in   sweat  
during   exercise   and   the   sensors   could   be  used   for   continuous   operation   for   up   to   2   h   before   the  
glucose  and  lactate  sensing  units  were  interchanged  for  fresh  sensor  arrays.  A  minimum  of  10  µμL  of  
sweat  was  required  before  any  sweat  analysis  could  be  achieved  [81].  The  sensors  were  placed  close  
to  the  skin,  to  allow  for  immediate  analysis  of  sweat  as  it  emerged.  Sweat  was  absorbed  into  a  water-­‐‑
absorbent   thin   rayon   pad   for   stable   and   reliable   glucose   readings,   placed   between   the   electrode  
   
sensors  and  skin.  This  flexible  wearable  sensing  system  is  a  promising  platform  for  tracking  multiple  
physiological  analytes  during  exercise.     
  
Figure  5.  A.  Flexible  glucose  sensor.  B.  Glucose  sensor  integrated  in  to  a  wearable  wristband  for  non-­‐‑
invasive  sensing  in  sweat.  Adapted  from  [81].  
Rogers  and  co-­‐‑workers   [82],  have  examined  a  range  of  porous  materials   that  can  be  used  for  
optimising   epidermal   characterisation   of   sweat   with   the   aim   of   developing   thin   (1   mm   thick),  
wireless,   stretchable   sensors   for   continuous   monitoring.   Some   of   the   soft   materials   investigated  
include  recycled  cellulose  sponge,  polyurethane  sponge,  polyvinyl  alcohol  sponge,  cellulose  paper  
and   silicone   sponge.   These  materials  were   chosen   for   their   ability   to   absorb   and   retain   sweat   by  
capillary  forces  when  in  contact  with  the  skin,  in  order  to  optimise  the  handling  and  analysis  of  the  
biofluid  by  eliminating  the  need  for  complex  microfluidic  systems  [82].  The  substrate  is  skin-­‐‑like  in  
nature,  which  makes  it  conformable  and  comfortable  to  wear  during  monitoring  periods.  It  also  is  
simple  to  integrate  with  a  range  of  electronic  sensors  and  communication  platforms,  such  as  a  smart  
phone  for  simple  colorimetric  measurements  [82].  Moreover,  by  employing  soft  skin-­‐‑like  polymeric  
materials,  irritation  during  long-­‐‑term  monitoring  sessions  could  be  reduced  as  direct  contact  of  the  
electrodes  with  the  skin  is  prevented,  by  having  the  hydrogel  sandwiched  between  the  skin  on  one  
side  and   the  metal   electrode   substrate  on   the  other.  The  device  developed  by  Rogers   et   al.   could  
successfully   monitor   the   volume   and   pH   of   sweat,   as   well   as   the   physiologically   relevant  
concentrations  of  copper  (Cu+)  and  iron  (Fe2+)  ions  (0.8–1  mg/L)  for  period  of  2  h  [82].  
Rogers   and   co-­‐‑workers   [83],   have   also   investigated   soft   ferromagnetic   materials   for   skin-­‐‑
interfaced   electrodes.   This   material   was   designed   for   intimate   and   adhesive   contact   with   skin  
ensuring   a   device   that   is   conformable   and   robust   enough   for   continuous   operation   compared   to  
conventional   hydrogel-­‐‑based   alternatives.   The   device   is   also   paired   with   a   separate   standing  
platform,  to  which  the  electrodes  are  magnetically  attached  to  facilitate  for  cleaning  or  replacement  
of  sensor  units  [83].  The  main  advantages  of  this  approach  included  the  conformability  and  resilience  
of  the  sensors  to  allow  for  natural  movements  on  body  during  sensing  periods  and  direct  integration  
of  the  wireless  electronics  for  data  collection  and  communication.  Moreover,  the  sensors  minimised  
noise   from  motion   artefacts   by   incorporating   a  magnetic   bi-­‐‑layer  material   [83].   In   comparison   to  
conventional   hydrogels,  which   are   known   to   shrink   or   swell   in   response   to   certain   analytes,   this  
magnetic  material  retained  its  shape  when  exposed  to  biofluids  or  air.  Continuous  operation  of  the  
device  was  demonstrated  for  a  period  of  two  days  (50  h)  [83].  Measurements  performed  included  
electroencephalograms   (EEGs)   to   monitor   electrical   activity   of   the   brain   [84],   electromyograms  
(EMGs)   to   detect   electrical   activity   in   muscles   [85],   electrocardiograms   (ECGs)   [86]   and  
electrooculography   (EOG)   [87].  The  designs  are   compatible  with   the  most   sophisticated  electrode  
potential  monitoring  systems  that  are  currently  commercially  available.  The  authors  also  suggest  that  
the  material  can  be  readily  adapted  for  detecting  other  epidermal  analytes  of  interest  [83].  
Overall,   although   sweat   sensing   for   diagnostic   data   is   very   promising,   there   are   also   some  
concerns  associated  with  this  sensing  fluid  [56].  The  main  challenges  include  (1)  limited  fundamental  
knowledge  about  the  sensing  fluid,  compared  to  other  physiological  fluids  such  as  blood  which  are  
much   better   understood;   (2)   sampling   issues   associated   with   sweat   production   by   exercising,  
iontophoretic   stimulation;   heat   or   carbon   dioxide   [76]   (3)   the   skin   surface   can   also   act   as   a  
contaminant;  as  sweat  traveling  across  the  skin  can  mix  with  fresh  emerging  sweat  and  contaminate  
   
the  sample  (4)  the  pH  range  of  sweat  fluctuates  over  a  wide  range  between  pH  4.0–6.8  which  can  
interfere  with  some  sensing  approaches  [77]  and  (5)  the  rate  of  sweat  production  is  variable  and  can  
be  quite  low  (1  nL/min/mm2)  [56].  However,  this  low  sweat  rate  can  be  compensated  for  by  increasing  
the  area  sampled  for  sweat  analysis.  Although  most  of  these  effects  can  be  adjusted  for  in  prototype  
technology  innovations,  some  biological  factors  such  as  the  variable  nature  of  sweat  pH,  and  variable  
concentrations  of  ions  such  as  sodium  and  chloride  remain  a  significant  hurdle.  Broad  pH  ranges  can  
affect  enzymatic  sensors  and  influence  the  concentration  of  weak  acids  or  weak  bases  in  sweat,  such  
as  phosphates,  chlorides  or  salts  of  organic  acids  like  lactic  acid.  Therefore,  these  concentrations  may  
be  observed  at  slightly  higher  concentrations  in  comparison  to  other  fluids,  such  as  blood  [56,88].  
2.2.4.  Breath  Analysis  
Breath  analysis  is  another  means  of  tracking  the  health  status  of  an  individual  [14,89].  Volatile  
organic  compounds  (VOCs)  are  generated  as  by-­‐‑products  from  metabolic  pathways  within  the  body.  
These  biomarkers  migrate  around  the  body  via  the  circulatory  system,  pass  over  the  alveolar  interface  
and  are  exhaled  in  breath  [90].  A  molecular  breath  signature  can  be  established  by  measuring  the  
ratio  between  VOCs  in  breath  [90,91].  This  signature  is  composed  of  over  3500  VOCs,  consisting  of  
hydrocarbons,   ketones,   aldehydes,   alcohols,   esters,   nitriles   and   aromatic   compounds,   whose  
concentrations  can  be  affected  by  specific  diseases  [90].  For  example,  112  of  these  VOCs  have  been  
found  to  be  specifically  related  to  cancer  [91].  
Nanomaterials  can  be  incorporated  into  sensing  elements  for  monitoring  acetone  concentrations  
in  breath,  as  an  alternative  to  glucose  monitoring  for  diabetes  [92].  Ethanol  and  methyl  nitrite  have  
also  been  identified  as  biomarkers  for  diabetes  [90].  Acetone  levels  in  blood  are  approximately  330  
times  higher  than  in  breath,  at  0.1–2  ppm  for  healthy  individuals’  post-­‐‑glucose  loading  and  reaching  
to  up  to  103.7  ppm  in  critically  ill  diabetic  patients  [59].  Therefore,  the  sensing  units  must  have  a  high  
sensitivity   to   detect   VOCs   in   the   nanomolar   to   picomolar   concentration   ranges,   where   recent  
examples  of  such  devices  lack  specificity  for  concentrations  of  biomarkers  relating  solely  to  diabetes  
[59].  Jiang  and  co-­‐‑workers  have  reported  a  breath  acetone  analyser,  which  can  detect  acetone  levels  
in  diabetic  patients  [59].  Unfortunately,  the  device  requires  a  controlled  external  atmosphere  in  order  
to   diagnosis   diabetes   accurately,   where   the   reported   diagnosis   accuracy   is   estimated   at   74%.  
However,   other   factors   can   affect   acetone   levels,   including   fasting,   exercising,   dieting   and   intra-­‐‑
individual  variation,  thereby  limiting  the  use  of  acetone  as  a  specific  biomarker  for  diagnosing  and  
monitoring  diabetes  [93].  
For   this   technology   to  be   fully   efficient,   the   sensor  must   also   integrate   easily   into   a  portable  
meter,   and   provide   a   means   for   non-­‐‑invasive,   inexpensive   and   qualitative   monitoring   to   be  
implemented  into  a  rapid  response  tool  for  early-­‐‑diabetes  diagnosis  [89–91].  Although  breath  can  be  
more   readily   evaluated   in   comparison   to   blood   or   urine,   there   are   some   shortcomings   when  
attempting  to  design  a  device  with  fast  analytical  responses  in  breath.  The  analysis  of  VOCs  in  breath  
is  more  challenging  due  to  external  air  interferents  and  the  wide  complex  range  of  VOCs  detectable,  
although  more  comprehensive  analysis  techniques  can  be  incorporated,  such  as  GC-­‐‑MS,  to  provide  
rich-­‐‑information   regarding   the   breath   composition   [16,89,91,93].   However,   the   device   currently  
remains   expensive   and   non-­‐‑portable,   although   significant   advances   in   miniaturisation   have  
occurred.  
Electronic-­‐‑nose  (e-­‐‑nose)  technology  has  also  been  applied  to  continuous  monitoring  of  breath.  
These  portable   sensors  were  designed   to  mimic  olfactory  sensing  by  breath  analysis  using  sensor  
arrays  that  generate  response  patterns  that  can  be  related  to  the  composition  of  breath  [59].  E-­‐‑noses  
have  been  primarily  designed  for  assessing  volatile  mixtures  of  biomarkers  or  VOCs  in  breath  for  
lung  diseases.  The  e-­‐‑nose  generates  response  patterns  when  exposed  to  the  breath  samples,  and  these  
patterns  are  compared  to  database  libraries  of  molecular  breath  signatures  for  known  diseases,  such  
as  chronic  obstructive  pulmonary  disease  (COPD)  [94],  upper  respiratory  tract  infections  (URTI)  [95]  
and  pulmonary  tuberculosis  (TB)  [96].  Currently  these  devices  have  found  applications  in  the  food  
[97],  environmental  and  chemical  industries  [98],  as  well  as  in  clinical  trials  for  the  recognition  of  lung  
cancer  [99],  asthma  [100],  pulmonary  arterial  hypertension  [101]  and  diabetes  [59].  However,  a  major  
   
obstacle,  which  must  be  overcome  before  these  devices  reach  the  consumer  market  is  the  elimination  
of   issues   involving  external  air   contaminants.   In  order   to   standardise   the   sampling  procedure   for  
accurate   detection,   stringent   control   to   remove   any   external   air   contaminants   is   necessary   for  
background  correction  of  the  device.  This  is  not  only  related  to  the  dead-­‐‑space  in  the  device,  but  also  
the  atmosphere  the  patient  is  exposed  to  [89].  In  order  to  reach  its  full  commercial  potential,  further  
development  and  standardisation  must  be  implemented.  Moreover,  controversy  still  exists  regarding  
the   reliability   of   this   approach   for   accurate   correlation   of   response   patterns   to   underlying   health  
conditions  [16,89].  
2.2.5.  Saliva  
Saliva   is   a   complex   fluid   containing   many   analytes   that   permeate   from   blood,   thereby   in  
principle  providing  a  useful  insight  in  to  a  person’s  emotional,  hormonal,  metabolic  and  nutritional  
state  [15,102].  As  a  result,  saliva  has  been  investigated  as  an  alternative  fluid  for  non-­‐‑invasive  glucose  
sensing,  with  glucose  levels  for  a  healthy  individual  ranging  from  0.23  to  0.38  mM  and  between  0.55  
and  1.77  mM  for  diabetics  [57].  Although  a  relationship  between  glucose  levels  in  blood  and  saliva  
obviously   exists,   it   is   not   well   understood,   and   relating   saliva   concentration   to   therapeutic  
intervention  is  therefore  more  challenging.  However,  saliva  offers  many  advantages  for  diagnostics,  
the  main  benefit  being  that  saliva  can  be  collected  in  a  non-­‐‑invasive  fashion.  As  a  result,  there  have  
been  many  emerging   technologies   reported   for   continuous  and  non-­‐‑invasive  glucose  detection   in  
saliva,   using   everyday   dental   platforms,   including  mouth   guards   and  dentures,   as  well   as   novel  
devices,  such  as  dental  tattoos  [15,103].  
Several  research  groups,  including  that  of  Kim  et  al.  [14,103],  have  investigated  the  potential  use  
of  a  mouth  guard  as  a  minimally  invasive  continuous  monitoring  platform  for  metabolite  sensing  in  
saliva.  This  sensing  platform  encompasses  a  printable  enzymatic  electrode,  based  on  lactate  oxidase,  
for  the  detection  of  salivary  lactate  (Figure  6)  with  high  sensitivity,  selectivity  and  stability  in  human  
saliva   samples   [103].   This   amperometric   electrochemical   sensing   approach   uses   a   poly-­‐‑
orthophenylenediamine  (PPD)/lactate  oxidase  reagent  layer  with  a  printable  Prussian-­‐‑blue  transducer,  
where  the  Prussian-­‐‑blue  reagent  acts  as  the  ‘artificial  peroxidase’  to  offer  a  highly  selective  detection  
approach   for   hydrogen   peroxide   in   the   catalytic   reaction   [103].   The   Prussian-­‐‑blue   reagent   was  
previously  used  for  oral  treatment  of  heavy  metal  poisoning,  such  as  thallium  and  caesium,  for  which  
it  is  widely  accepted  as  safe  under  physiological  conditions  and  at  high  oral  dosages.  PPD  has  also  
been  commonly  used  for  electropolymeric  entrapment  of  oxidases,  and  its  relatively  low  oxidation  
potential   in   comparison   to   other   electroactive   species,   such   as   ascorbic   acid   or   urea,   facilitates  
protection   of   the   biosensor   surface,   and   enhances   stability   of   the   sensing   components   [103].   This  
sensing  approach  also  has  the  potential  to  be  used  for  glucose  biosensing,  by  replacing  the  lactate  
sensor  with  a  glucose  sensor,  as  the  sensing  principles  of  these  electrochemical  biosensors  and  their  
associated  electronics  are  very  similar.  
   
  
Figure   6.   Lactate   sensing  mouth   guard   for   non-­‐‑invasive   continuous   lactate   sensing   in   saliva.   (A)  
Mouth   guard   sensing   platform   showing   integrated   printable   3-­‐‑electrode   system,   with   a   lactase  
enzyme  immobilised  on  the  working  electrode;  (B)  Detailed  representation  of  the  working  electrode  
and  components.  Adapted  from  [103].  
Intraoral   dental   accessories   have   also   been   of   interest   for   non-­‐‑invasive   and   continuous  
monitoring  to  provide  information  regarding  a  patient’s  health  status.  A  tooth  has  the  potential  to  act  
as  a  continuous  monitoring  device  as  it  is  in  constant  contact  with  the  patient’s  saliva.  Mannoor  et  al.  
[104]   have   developed   a   bacterial   detection   approach  whereby   a   graphene-­‐‑based   nanosensor  was  
printed  on   to  water-­‐‑soluble  silk  and  transferred  on   to   tooth  enamel   (Figure  7).  This  sensing   tooth  
incorporates  a  resonant  coil  to  prevent  the  need  for  a  power  source  and  external  connections.  The  
device  operates  by   the  self-­‐‑assembly  of  antimicrobial  peptides  on   to   the  single  sheet  of  graphene,  
where  the  bio-­‐‑selective  analysis  of  bacteria  can  be  performed  at  a  single  cellular  level.  Preliminary  
results  showed  great  specificity,  response  time  and  single-­‐‑molecule  detection  abilities  for  this  sensor,  
however   this   sensing   application   must   still   be   tested   on-­‐‑body   for   real-­‐‑time   analysis   [104].   This  
approach  could  potentially  be  adapted  for  detection  of  other  analytes  such  as  glucose,  by  means  of  a  
chemical  glucose  sensor  immobilised  on  to  a  water-­‐‑soluble  silk  layer  attached  to  the  tooth  enamel.  
  
Figure   7.   Glucose-­‐‑sensing   tattoo   printed   on   to   a   tooth   platform   as   a   non-­‐‑invasive   continuous  
monitoring  device.  (A)  Graphene  printed  on  bio-­‐‑resorbable  silk  with  contacts  containing  a  wireless  
coil;   (B)  Bio-­‐‑transfer  of  sensor  on  to   tooth  enamel;   (C)  Magnified   image  of   the  sensing  unit  with  a  
wireless   readout   system;   (D)   Self-­‐‑assembly   of   pathogenic   bacteria   bound   by   peptides   on  
nanotransducer  surface.  Adapted  from  [104].  
Zhang   and   co-­‐‑workers   [71]   have   fabricated   a   disposable   microfluidic   device   that   has   been  
developed   as   a   diagnostic   tool   for   quantifying   saliva-­‐‑glucose   concentrations   by   electrochemical  
methods.   The   glucose-­‐‑sensing   chip   houses   a   working   electrode,   a   counter   electrode   and   reference  
electrode  [71].  The  intricate  device  design  consisted  of  a  working  electrode  functionalised  with  single-­‐‑
walled   carbon   nanotubes,   to   promote   electron   transfer   for   the   glucose   oxidase   reaction.   Gold  








enzyme   attachment.   Chitosan,   a   non-­‐‑toxic   biocompatible   polysaccharide,   was   also   employed   for  
promoting   film   formation   and   adhesion   characteristics   in   order   to   enhance   glucose   oxidase  
immobilisation  [71].  This  device  showed  impressive   linearity  for  glucose  detection  in  the  range  of  
0.017–0.8  mM  [71],  correlating  to  saliva-­‐‑glucose  levels  in  healthy  patients.  
2.2.6.  Ocular  Fluid  
The  fluid  surrounding  the  eye  and  ocular  tissue,  also  known  as  the  aqueous  humour,  contains  
many  analytes  present  in  blood.  This  complex  fluid  can  be  excreted  from  the  body  as  an  extracellular  
fluid  in  the  form  of  tears.  Analytes  found  in  this  fluid,  such  as  glucose,  ascorbic  acid,  lactate,  proteins,  
peptides,  hormones,  carbohydrates,  electrolytes,  lipids  and  chloride,  can  offer  great  insight  into  an  
individual’s  health  status  [15,105].  As  a  result,  this  fluid  has  been  investigated  for  non-­‐‑invasive  and  
continuous  glucose  monitoring.  
Recently,  the  Google[X]  lab  (Mountain  View,  CA,  USA)  and  Novartis  (Basel,  Switzerland)  have  
collaborated   on   the   development   of   glucose   sensing   technologies   in   the   aqueous   humour.   The  
Google[X]  lab  was  founded  to  “find  new  solutions  to  big  global  problems”  with  diabetes  falling  into  
this   category   [106].   In   2014,   they   announced   their   goal   to   create   a   smart-­‐‑contact   lens,  which   they  
hoped  would  overcome  glucose-­‐‑monitoring  obstacles  associated  with  current  methods,  which  are  
either  invasive,  in  the  case  of  implanted  wearable  devices  or  non-­‐‑continuous,  in  the  case  of  the  finger-­‐‑
pricking   approach.   This   novel   technology   incorporates   an   electrochemical   battery-­‐‑operated  
enzymatic  glucose  sensor,  utilising  the  enzyme  glucose  oxidase  (GOx),  in  a  microchip  sandwiched  
between  two  layers  of  a  soft  contact  lens,  as  represented  in  Figure  8  [106,107].  A  tiny  sensor  relays  
data  to  a  mobile  device,  from  which  the  patient  or  medical  practitioner  can  read  the  corresponding  
glucose  levels  in  the  ocular  fluid  [108-­‐‑110].  This  redox  reaction  is  monitored  through  the  production  
of  hydrogen  peroxide  at  the  working  electrode  to  quantify  the  glucose  concentration  in  the  ocular  
fluid  [111].  However,  there  are  disadvantages  to  an  electrochemical  sensing  approach,  which  can  be  
related   to   the  use  of   enzymes   leading   to   the  production  of   corrosive  hydrogen  peroxide   as   a  by-­‐‑
product  or  interference  from  electroactive  species  in  the  ocular  fluid,  such  as  ascorbic  acid,  lactate  or  
urea   [105,109].   Blinking  may   also   stimulate   a  movement   artefact   in   the  wireless   sensor   signal.   In  
addition  to  the  battery  source  embedded  in  the  lens,  an  external  power  source  must  be  provided  for  
enabling  efficient  sensor  function  and  to  facilitate  wireless  communication  of  the  data.  This  is  a  very  
active  area  of  research,  with  multiple  approaches  under  investigation  into  the  production  of  a  safe  
biocompatible  battery  powered  device  [112].  These  include  additional  power  sources  external  to  the  
device  that  would  wirelessly  transmit  power,  for  example  through  radio  frequency  induction,  using  
solar  cells  to  harvest  energy,  or  using  biofuel  cells.  Biofuel  cells  could  be  used  in  a  second  wearable  
device   to   supply   chemical   energy,   which  would   be   converted   to   electrical   energy,   to   power   the  
biosensor.  This  separate  power  source  would  need  to  be  within  close  proximity  of  the  eye  in  order  
for  the  smart-­‐‑contact  lens  to  function  efficiently  [112].  
  
Figure  8.  Google  and  Novartis  smart-­‐‑contact  lens.  Adapted  from  [107].  
   
Using   a   contact   lens   as   a   sensing   platform   does   hold  many   advantages,   including   real-­‐‑time  
continuous  and  non-­‐‑invasive  glucose  monitoring,  as  the  lens  would  be  in  constant  contact  with  the  
aqueous  ocular  fluid  [20,105,113].  Disposable  contact  lenses  are  typically  replaced  every  24  h,  which  
is  a  reasonable  period  for  reliable  continuous  biosensor  operation.  Blinking  and  tear  secretion  also  
allow   for   natural,   fresh   sample   replenishment   for   accurate   glucose   concentration   measurements  
throughout  the  day  [105].  By  incorporating  a  glucose  sensor  in  to  a  commercially  available  lens,  not  
only  could  this  lens  provide  a  form  of  corrective  vision  but  a  monitoring  function  too  [20,105,110].  It  
is  well  known  that  critical  side  effects  associated  with  diabetes  are  eye  damage  or  blindness  [20],  due  
to  glycation  of  proteins  in  the  blood  vessels  of  the  eye  [37].  To  account  for  such  ocular  deteriorations  
a  detection  function,  potentially  based  on  imaging,  for  glycation  of  vascularised  tissues  could  later  
be  incorporated  in  to  the  lens.  
Other  research  groups,  such  as  Yao  et  al.  have  worked  with  Google,   to   investigate  the  use  of  
contact  lenses  as  a  biosensing  platform  for  quantifying  glucose  concentrations  in  the  ocular  humour.  
GOx  was  the  enzyme  employed  in  an  amperometric  glucose  sensor  for  this  purpose.  The  sensor  was  
immobilised  as  a  screen-­‐‑printed  structure  on  to  a  polymeric  substrate  in  the  shape  of  a  lens  [72].  An  
amperometric   sensing   method   was   chosen   since   the   oxidation   and   reduction   potentials   of   this  
reaction  can  be  directly  associated  with  a  measurable  current   signal,  which   is  proportional   to   the  
concentration  of  the  analyte  being  quantified  [105].  The  preliminary  results  showed  some  promise,  
with  the  lens  reported  to  sense  glucose  in  the  range  of  0.1–0.6  mM  [72].  This  correlates  with  ocular  
glucose   levels   of   0.05–0.5  mM   for   healthy   individuals,   increasing   to   up   to   5  mM   for   critically   ill  
diabetics  [20].  The  ocular  glucose  levels  in  comparison  to  blood-­‐‑glucose  levels  are  approximately  10  
times  smaller  with  a  lag  time  of  about  10  min  [14,105,114].  Although  this  smart  lens  showed  rapid  
response  times  of  up  to  20  s  and  good  reproducibility  [72],  it  did  not  manage  to  demonstrate  non-­‐‑
invasive  and  continuous  glucose-­‐‑monitoring.  Many  issues  associated  with  tear  fluid  interference  and  
challenges  related  to  powering  the  device  are  still  under  development  [105].  Kagie  et  al.  [115]  and  
Iguchi   et   al.   [114]   proposed   an   alternatively   designed   sensor,   using   the   same   glucose   sensing  
methodology,  which  was  inserted  into  the  tear  canal.  Kagie  et  al.  [115]  showed  that  the  sensor  could  
be   fabricated   by   screen-­‐‑printing   approaches   and   Iguchi   et   al.   [114]   demonstrated   the   sensor  
production  by  microfabrication  techniques.  The  sensors  fabricated  by  both  approaches  were  reported  
to  have  high  selectivity  for  ocular-­‐‑glucose,  but  further  tests  are  required  to  determine  the  effects  of  
interfering  electroactive  species  such  as  ascorbic  acid,  lactate  or  urea,  all  of  which  are  present  in  the  
aqueous  humour  [114,115].     
Recently,  Badugu  et  al.  introduced  an  optical  chemical  sensor  for  glucose  detection  in  the  ocular  
fluid  [20].  In  this  case,  they  used  boronic  acids  (BAs)  attached  to  a  fluorescent  component  to  directly  
sense  glucose  by  optical  means  [20,21,36–39,45,116,117].  On  interaction  of  the  fluorescent  BA  sensors  
with  increasing  saccharide  concentrations,  a  decrease  in  the  fluorescence  intensity  of  the  BA  sensors  
occurred.  For  example,  when  using  a  fluorescent  quinoline  moiety  a  decrease  of  ~30%  was  observed  
upon  introduction  of  100  mM  glucose  [20,21].  This  sensing  mechanism  was  attributed  to  fluorescence  
quenching  via  a  charge  neutralisation-­‐‑stabilisation  mechanism.  The  anionic  boronate  ester  formed  on  
glucose   binding  was   stabilised  by   a  positively   charged  N  atom   in   the   quinoline   structure,  which  
consequently   quenched   the   fluorescence   of   the   BA   sensor   [20,21].   The  main   advantage   for   using  
chemical   sensors   over   enzymatic   sensors   is   that   the   sensing   detection   and   communication  
mechanisms  do  not  require  any  power.  Chemical  sensing  by  optical  means,  eliminates  the  need  for  
external  sources  of  energy  to  power  the  device  when  the  material  is  self-­‐‑reporting.  The  concentration  
changes   detected   by   the   sensor   induce   an   optical   change   in   the   material,   which   are   used   to  
communicate  the  analytical  response.  As  a  result,  by  using  a  chemical  sensing  approach  the  sensing  
components  can  be  greatly  simplified.  Moreover,  the  production  of  corrosive  hydrogen  peroxide  is  
eliminated,  overcoming  a  significant  disadvantage  of  the  electrochemical  sensing  approach  [20].  
Other  groups  working  towards  non-­‐‑invasive  monitoring  of  glucose  in  the  ocular  fluid  include  
Jeong,  et  al.  and  Microsoft  Inc.  (Redmond,  WA,  USA)  in  collaboration  with  Evans  and  co-­‐‑workers.  
Jeong,   et   al.   [118]   have   developed   Raman   sensitive,   silver   plasmonic,   nanostructures   that   are  
responsive  to  glucose.  These  nanostructures  used  solvent-­‐‑assisted  nanotransfer  printing  to  attach  the  
   
plasmonic   glucose   sensing   material   on   to   a   commercially   available   contact   lens.   Nanotransfer  
printing   in   this   way   created   narrow   passageways   or   ‘hot   spots’   in   the   nanostructure,   to   take  
advantage   of   the   surface-­‐‑enhanced   Ramen   scattering   in   the   sensing   material   to   detect   small  
molecules,  such  as  glucose,  non-­‐‑invasively  in  the  ocular  fluid.  The  approach  is  clever  in  that  it  uses  
retina-­‐‑safe  laser  excitation  to  measure  glucose  concentrations  within  the  range  of  0.1–10  mM  [118].  
Microsoft,   in   collaboration  with  Drew   Evans’   group   from   the  University   of   South  Australia  
(Mawson   Lakes,   SA,   Australia),   have   designed   hydrophilic   organic   electrodes   that   could   be  
incorporated   in   to   flexible   hydrogels,   such   as   a   contact   lens   [119].   In   their   approach,   they   have  
fabricated  polymeric  coatings  that  were  engineered  to  be  biocompatible  and  conducting,  which  could  
be  grown  directly  on   to   a   contact   lens.  Evans  and   co-­‐‑workers,  deposited   the   conductive  polymer  
poly(3,4-­‐‑ethylene-­‐‑dioxythiophene  (PEDOT)  on  to  the  lens  using  oxygen  plasma  techniques.  This  lens  
was   designed   to   advance   the   development   of   silicone   hydrogels   with   technologically   relevant  
properties,   such   as   conductivity,   to   pave   the   wave   for   conductive   hydrogel   electrodes   [119].  
Ultimately,   this   lens   would   self-­‐‑report   relating   optical   changes   to   glucose   concentrations.   An  
advantage  of  this  passive  device  is  that  no  batteries  or  wireless  connections  are  required  to  receive  
and  transmit  crucial  information.  Currently,  work  is  underway  in  the  group  to  test  the  robustness  of  
the   coatings,   to   further   develop   the   lens   towards   disease   diagnosis   and   monitoring,   and   other  
alternatively  interesting  applications  for  military  camouflage  apparel,  where  electricity  would  induce  
a  reversible  colour  change  in  the  polymer  from  brown  to  green  [120].  
3.  Conclusions  
Wearable  sensors  have   the  potential   to  play  a  major  role   in   the  continuous  and  non-­‐‑invasive  
monitoring   of   biomarkers   for   diabetes   and   other   disease   conditions.   The   majority   of   sensors  
described   in   this   review   still   require   further   clinical   evaluation   before   they   can   be   approved   for  
medical  use.  The  interest  of  companies  such  as  Google,  Novartis  and  Microsoft  suggests  there  is  really  
significant  market  potential  for  new  approaches  to  self-­‐‑monitoring  and  diagnosing.  A  key  enabling  
step  will  be  to  create  a  clearer  understanding  of  the  relationship  between  the  diagnostically  relevant  
concentrations   of   key   disease  markers   in   blood   compared   to   other   physiological   fluids.   Existing  
wearable  devices  such  as   fitness  bands  and  smartwatches,  which  already  dominate   the  consumer  
technology   market,   provide   an   information   base   that   can   be   expanded   to   encompass   disease  
monitoring  or  diagnosis,  and  provide  a   tangible   impact  on  health  and  wellness.  However,  unless  
these  wearable  technologies  can  provide  additional  insights  into  the  wearer’s  health,  be  integrated  in  
to  clinical  practices  and  promote  actionable  behavioural  change,  their  positive  impact  may  continue  
to  be  limited.  
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